Day: November 3, 2024

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

Written by Customer Service on . Posted in Public Companies.

MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialized diagnostic radiopharmaceuticals1 for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional pass-through payment period (“pass-through”). This is a significant decision for patients and hospitals, with the change facilitating equitable access to advanced imaging agents for all patients into the future.  In 2025, the separate payments under the Hospital Outpatient Prospective Payment System (OPPS) will be based on Mean Unit Cost (MUC), derived from hospital claims data and apply to any specialized diagnostic radiopharmaceutical...

Continue reading

Complete Solar to Report Third Quarter Financial and Operational Results on November 13, 2024

Written by Customer Service on . Posted in Public Companies.

LEHI, Utah, Nov. 03, 2024 (GLOBE NEWSWIRE) — Complete Solar Holdings, Inc. d/b/a Complete Solar (“Complete Solar” or the “Company”) (Nasdaq: CSLR), a solar technology, services, and installation company, today announced it will release its financial and operational results, for the third quarter of 2024, after market close on Wednesday, November 13, 2024. T.J. Rodgers and the Complete Solar management team will also host a webcast conference call on November 13, 2024, at 5:00 PM ET. Interested parties may access the webcast by registering here, or by visiting the Events page within the Investor Relations section of Complete Solar’s company website at: https://investors.completesolar.com/news-events/events. Please log into the webcast at least 10 minutes prior to the start of the event. A replay of the webcast will be available...

Continue reading

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, at an exercise price of US$44.14 per share. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately US$28.75 million. The Company intends to use the net proceeds from the offering for general corporate purposes. The ordinary shares issuable upon exercise of the warrants are registered...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.